The FDA recommends semaglutide for weight loss if you meet one of the following criteria: Have a body mass index (BMI) of 27kg/m2 or greater and at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol Have a BMI of 30kg/m2 or greater Avoid semaglutide if you have: History of medullary thyroid cancer History of gallbladder disease History of pancreatitis Multiple endocrine neoplasia syndrome type 2 (MEN2) Conclusion: Semaglutide for Weight Loss Semaglutides effectiveness in reducing body fat can be attributed to its impact on appetite regulation, gastric emptying, and energy expenditure
The secondary patents, e.g., in the US, are not set to expire until 2033, thus providing Novo Nordisk with prolonged market exclusivity and delaying the launch of generics in other territories
Compounded drugs are not FDA-approved and do not have to undergo any safety, effectiveness, or manufacturing reviews
Compounded semaglutide is administered using a U-100 insulin syringe and measured in units rather than milligrams
Visit MedifastInc.com and OPTAVIA .com for more information and follow @Medifast on X and LinkedIn